Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study).
Sang-Man JinSoo LimHyuk-Sang KwonIe B ParkKyu J AhnCheol-Young ParkSu K KwonHye S KimSeok W ParkSin Gon KimMin Kyong MoonEun S KimChoon Hee ChungKang S ParkMikyung KimDong J ChungChang B LeeTae H KimMoon-Kyu LeePublished in: Diabetes, obesity & metabolism (2020)
In this study, the glucose-lowering efficacy of evogliptin was non-inferior to linagliptin. It was maintained at week 24 with a 0.94% reduction in HbA1c. Evogliptin therapy improved glycaemic variability without causing any serious adverse events in patients with type 2 diabetes.